TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02737059
Drug: codeine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 times daily (placebo will be made to match the codeine)
Study: NCT00133354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
Study: NCT02042001
Drug: Immediate switch to TDF/FTC/RPV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01508858
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Study: NCT01508858
Drug: levonorgestrel / ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
Study: NCT02042001
Drug: Switch to TDF/FTC/RPV after 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
Study: NCT00615316
Drug: Guaraná
Normalized name: GUARANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaraná extract 75mg/day
Study: NCT00615316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1tab/d
Study: NCT02676622
Drug: Preparative regimen 4-6 weeks after Leukapheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1
Study: NCT01166945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study: NCT00368849
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
Study: NCT02999854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
Study: NCT00875459
Drug: VIAject™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection 25 IU/mL
Study: NCT02827708
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily.
Study: NCT00989014
Drug: CD07805/47
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Topical Gel
Study: NCT00989014
Drug: CD07805/47
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18% Topical Gel
Study: NCT00989014
Drug: CD07805/47
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07% Topical Gel
Study: NCT00989014
Drug: CD07805/47 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Topical Gel
Study: NCT00969150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT00102102
Drug: [18F]SPA-RQ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01654731
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04501666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo as SC injection.
Study: NCT02953314
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003150
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003150
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003150
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03925740
Drug: MI Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of MI varnish material versus the standard 1.23% APF.
Study: NCT03925740
Drug: PreviDent Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of PreviDent Varnish material versus the standard 1.23% APF.
Study: NCT03925740
Drug: 1.23% APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1.23% APF application
Study: NCT00631566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
Study: NCT03387046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
Study: NCT00118794
Drug: Lumefantrine-artemether (Coartemether )
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04553536
Drug: Esketamine, Sulfentanil or/and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
Study: NCT02184247
Drug: anhydrous theophylline, 350 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184247
Drug: anhydrous theophylline, 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01065623
Drug: BAY79-4620
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
Study: NCT00099346
Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01272778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, single acute dose
Study: NCT00245570
Drug: Comparator: Placebo (montelukast)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose matching-image placebo to montelukast tablet in two of three treatment periods
Study: NCT00245570
Drug: Comparator: Placebo (salmeterol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
Study: NCT03418480
Drug: BNT113
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine
Study: NCT01991574
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01991574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylcellulose capsules
Study: NCT00152854
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1g po qid
Study: NCT00152854
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1g po qid for 7 days
Study: NCT00152854
Drug: placebo, sugar pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03794323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04264962
Drug: Yang Yin Fu Zheng Jie Du therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Study: NCT00128947
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00128947
Drug: Mycophenolate 7-O-Phenolic Glucuronide
Normalized name: TETRAHYDROCURCUMIN .BETA.-O-GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02450903
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LDK378 750mg once daily
Study: NCT00604539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
Study: NCT03967964
Drug: Dehydroepiandrosterone 2.2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with 2.2 grams DHEA.
Study: NCT03967964
Drug: Dehydroepiandrosterone 1.5 g/Testosterone 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
Study: NCT03967964
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal ring with 35 mg testosterone.
Study: NCT03967964
Drug: Testosterone Topical Gel
Normalized name: Testosterone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing 1% testosterone.
Study: NCT03418974
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
Study: NCT00710554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT00841074
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash spray application of \~1.3 ml twice a day.
Study: NCT02045368
Drug: IGF-Methotrexate conjugate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
Study: NCT01409564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
Study: NCT01036035
Drug: THVD-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug
Study: NCT01036035
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug
Study: NCT04615923
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration: Oral~Dose: one capsule twice daily
Study: NCT02282020
Drug: Single agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study: NCT02244489
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
Study: NCT00745147
Drug: Chinese herbal formula (CCH1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
Study: NCT02561650
Drug: COV155
Approvals — FDA: no, EMA: no, PMDA: no
Description: COV155 tablets
Study: NCT03518073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00475176
Drug: S-adenosyl methionine for Chronic Liver Disease
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03804879
Drug: Standard of Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Study: NCT00221754
Drug: Pravastatin (drug)
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01404390
Drug: BAY80-6946
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg/ kg, iv, day 1,8 and 15, every 28 days
Study: NCT01404390
Drug: BAY80-6946
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8mg/ kg, iv, day 1,8 and 15, every 28 days
Study: NCT01305850
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study: NCT00100815
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
Study: NCT01647282
Drug: locally-applied minocycline HCl (1 mg)
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00826020
Drug: Omegaven™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
Study: NCT04237090
Drug: Lactose pill
Normalized name: lactose Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural product number : 00501190
Study: NCT01953341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing no active drug
Study: NCT01830660
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01011660
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Study: NCT00938379
Drug: 20% deet insect repellent
Approvals — FDA: no, EMA: no, PMDA: no
Description: skin-applied repellent lotion
Study: NCT00938379
Drug: placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical base formulation of lotion but without any deet active
Study: NCT01216280
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg placebo capsules administered orally with water, b.i.d.
Study: NCT00965094
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
Study: NCT00965094
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Study: NCT03996460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food.
Study: NCT02491450
Drug: Heterosofir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT04258098
Drug: Oral antibiotics ( Streptomycin ,metronidazole )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
Study: NCT00477217
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00982592
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00982592
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02929121
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Study: NCT02929121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study: NCT03446573
Drug: DTG + 3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
Study: NCT03446573
Drug: TAF based regimen (TBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive their TBR.
Study: NCT03646188
Drug: Placebo-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
Study: NCT03646188
Drug: 25 µg doxorubicin-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
Study: NCT03646188
Drug: 50 µg doxorubicin-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
Study: NCT03646188
Drug: 100 µg doxorubicin-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
Study: NCT03646188
Drug: 200 µg doxorubicin-containing MNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
Study: NCT03123588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide-placebo administered orally BID
Study: NCT03123588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib-placebo administered orally BID.
Study: NCT00741949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution infusion
Study: NCT02993302
Drug: 1α-D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were given PTU and 1α-D3
Study: NCT02993302
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were given PTU and placebos
Study: NCT00756444
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
Study: NCT01018056
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
Study: NCT01018056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
Study: NCT04260607
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion.
Study: NCT03847090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Study: NCT00609973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid for 6 months
Study: NCT02181738
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03128346
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen
Study: NCT03128346
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV, fentanyl
Study: NCT03412890
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
Study: NCT00104715
Drug: antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03306121
Drug: TPF+CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
Study: NCT00968942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Study: NCT01968668
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg BAY94-8862 tablet once daily in the morning
Study: NCT01968668
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg BAY94-8862 tablet once daily in the morning
Study: NCT01968668
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BAY94-8862 tablet once daily in the morning